Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors.
SARS-CoV-2
T cell subsets
cellular immunity
function
immune activation
non-seroconvertor
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
11
2021
accepted:
29
03
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
The role of T cells in the control of SARS-CoV-2 infection has been underestimated in favor of neutralizing antibodies. However, cellular immunity is essential for long-term viral control and protection from disease severity. To understand T-cell immunity in the absence of antibody generation we focused on a group of SARS-CoV-2 Non-Seroconvertors (NSC) recovered from infection. We performed an immune comparative analysis of SARS-CoV-2 infected individuals stratified by the absence or presence of seroconversion and disease severity. We report high levels of total naïve and low effector CD8+ T cells in NSC. Moreover, reduced levels of T-cell activation monitored by PD-1 and activation-induced markers were observed in the context of functional SARS-CoV-2 T-cell responses. Longitudinal data indicate the stability of the NSC phenotype over three months of follow-up after infection. Together, these data characterized distinctive immunological traits in NSC including skewed cellular distribution, low activation and functional SARS-CoV-2 T-cell responses. This data highlights the value of T-cell immune monitoring in populations with low seroconversion rates in response to SARS-CoV-2 infection and vaccination.
Identifiants
pubmed: 35619701
doi: 10.3389/fimmu.2022.815041
pmc: PMC9128381
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
815041Informations de copyright
Copyright © 2022 Kilpeläinen, Jimenez-Moyano, Blanch-Lombarte, Ouchi, Peña, Quirant-Sanchez, Perez-Caballero, Chamorro, Blanco, Martínez-Caceres, Paredes, Mateu, Carrillo, Blanco, Brander, Massanella, Clotet and Prado.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Virol. 2016 Jun 10;90(13):6148-6158
pubmed: 27122576
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Nat Med. 2007 Jan;13(1):46-53
pubmed: 17173051
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33256890
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33533915
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
PLoS One. 2021 Jan 13;16(1):e0245556
pubmed: 33439908
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Clin Med. 2019 Dec 01;8(12):
pubmed: 31805700
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
J Infect Dis. 2015 Mar 15;211(6):936-46
pubmed: 25249264
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Front Immunol. 2020 Oct 06;11:581338
pubmed: 33123167
Cell Rep Med. 2020 Sep 22;1(6):100092
pubmed: 32904468
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Lancet Respir Med. 2021 Feb;9(2):e20-e21
pubmed: 33417829
Immunity. 2021 May 11;54(5):1066-1082.e5
pubmed: 33951417
Front Immunol. 2021 Jul 12;12:687449
pubmed: 34322120
PLoS Pathog. 2014 Aug 28;10(8):e1004345
pubmed: 25167059
BMJ. 2020 Dec 2;371:m4709
pubmed: 33268462
Sci Rep. 2021 Jan 28;11(1):2608
pubmed: 33510275
JAMA Netw Open. 2021 Feb 1;4(2):e210337
pubmed: 33576815
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Nature. 2020 Sep;585(7825):339-341
pubmed: 32929257
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Mech Ageing Dev. 2004 Sep;125(9):615-8
pubmed: 15491679
Cell Rep. 2021 Mar 16;34(11):108852
pubmed: 33730580
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Biomed Pharmacother. 2021 Sep;141:111794
pubmed: 34153851
Front Immunol. 2020 Mar 05;11:182
pubmed: 32194543
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33058753
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Immunity. 2021 Jan 12;54(1):44-52.e3
pubmed: 33338412
J Intern Med. 2021 Apr;289(4):450-462
pubmed: 33020988
Med (N Y). 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155
PLoS One. 2006 Dec 20;1:e24
pubmed: 17183651
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652